Groupama Asset Managment Purchases 101,225 Shares of AstraZeneca PLC (NASDAQ:AZN)

Groupama Asset Managment increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 22.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 543,398 shares of the company’s stock after buying an additional 101,225 shares during the period. Groupama Asset Managment’s holdings in AstraZeneca were worth $42,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of AZN. Stratos Wealth Advisors LLC raised its position in AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares during the period. Carnegie Investment Counsel raised its position in AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after acquiring an additional 138 shares during the period. Crumly & Associates Inc. raised its position in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Sunpointe LLC raised its position in AstraZeneca by 4.5% in the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock worth $267,000 after acquiring an additional 147 shares during the period. Finally, Argonautica Private Wealth Management Inc. raised its position in shares of AstraZeneca by 4.0% in the second quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company’s stock valued at $302,000 after purchasing an additional 149 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $68.58 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The stock has a market cap of $212.64 billion, a PE ratio of 32.81, a P/E/G ratio of 1.22 and a beta of 0.45. The firm has a 50 day simple moving average of $71.27 and a two-hundred day simple moving average of $77.08.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the company earned $0.87 EPS. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts predict that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.